Turkey Pharmaceuticals Market, By Drug Type (Branded Drugs, Generic Drugs), By Product Type (Prescription Drugs, Over-The-Counter Drugs), By Application (Oncology, Metabolic Disorder, Cardiovascular, Anti-infective, Musculoskeletal, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Pharmacy), By Region, Competition, Forecast & Opportunities 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 9.42 Billion
CAGR (2026-2031)	8.99%
Fastest Growing Segment	Generic Drugs
Largest Market	Marmara
Market Size (2031)	USD 15.79 Billion

Market Overview

The Turkey Pharmaceuticals Market will grow from USD 9.42 Billion in 2025 to USD 15.79 Billion by 2031 at a 8.99% CAGR. The Turkey Pharmaceuticals Market encompasses the research, development, manufacturing, distribution, and sale of medicinal products for human and animal health, including prescription drugs, over-the-counter medications, and biological products. Market growth is primarily driven by increasing healthcare expenditure, a growing and aging population, and the rising prevalence of chronic diseases. According to the Pharmaceutical Manufacturers Association of Turkey (İEİS), the Turkish pharmaceutical market reached 430.8 billion TRY in 2025, with unit sales totaling 2.7 billion units during the same period.

Despite these foundational growth factors, the market faces a significant challenge in the form of government-imposed pricing pressures and frequent adjustments to reference pricing. These regulatory actions directly impact manufacturer profitability and can constrain investment in innovative treatments and local production capabilities, thereby impeding overall market expansion.

Key Market Drivers

Aging Demographics Expand Pharmaceutical Demand
Expanding and aging population demographics significantly contribute to the growth of the Turkey Pharmaceuticals Market by increasing the overall demand for healthcare services and medicinal products. As the population ages, the prevalence of chronic and age-related diseases naturally rises, requiring ongoing pharmaceutical interventions. For instance, according to the Turkish Statistical Institute, Turkey's population aged 65 and over reached 9,583,059 in 2025, marking a notable demographic shift that directly expands the patient pool needing pharmaceuticals. This demographic trend necessitates a broader range of medications for conditions such as cardiovascular diseases, diabetes, and various geriatric ailments, driving demand across therapeutic categories.

Government Support and R&D Investment Boost Domestic Pharma
Government support for domestic pharmaceutical production and research and development acts as another crucial driver by fostering local manufacturing capabilities and innovation. Strategic initiatives aim to reduce reliance on imports and enhance self-sufficiency in critical pharmaceutical supplies. In September 2025, Turkey increased its annual research and development allocation to $16 billion, demonstrating a commitment to advancing technological independence within various sectors, including pharmaceuticals. This focus on local production and R&D helps stimulate investment in advanced manufacturing techniques and the development of new treatments. Furthermore, according to the Pharmaceutical Manufacturers Association of Turkey (İEİS), in 2024, Turkey's pharmaceutical exports reached $2.3 billion, highlighting the growing international presence and capabilities of the domestic industry.

Download Free Sample Report

Key Market Challenges

Pricing pressures and reference pricing constrain profitability
The primary challenging factor impeding the growth of the Turkey Pharmaceuticals Market is government-imposed pricing pressures and frequent adjustments to reference pricing. These regulatory actions directly impact the financial viability of pharmaceutical manufacturers by compressing profit margins. The consistent downward pressure on drug prices, often benchmarked against the lowest prices in European Union countries, reduces the revenue generated from product sales, making it difficult for companies to achieve sustainable returns on their investments.

Pricing measures dampen investment in R&D and local manufacturing
This challenging environment discourages crucial investment in innovative treatments and the expansion of local production capabilities. Such pricing policies diminish the incentive for pharmaceutical firms to allocate capital towards research and development for new drugs or to upgrade existing manufacturing facilities within Turkey. According to a survey conducted by the Association of Research-Based Pharmaceutical Companies (AIFD) earlier in 2026, more than half of the 23 research-based pharmaceutical companies reported having to cancel investments due to government measures, primarily related to drug pricing. This directly constrains the market's potential for expansion and the introduction of advanced therapies.

Key Market Trends

Biopharmaceutical and Biosimilar Market Growth
The Turkey Pharmaceuticals Market is significantly influenced by the continued expansion of the biopharmaceutical and biosimilar market. This trend reflects a global shift towards advanced therapeutic solutions for complex diseases, with Turkey actively participating in the adoption and, increasingly, the local production of these high-value products. The growing accessibility of biosimilars, which offer more affordable alternatives to originator biologics, plays a vital role in broadening patient access to essential treatments across various therapeutic areas such as oncology and autoimmune conditions. According to the TURKIYE PHARMACEUTICAL SECTOR REPORT, October 2024, total sales of biotechnological products in Turkiye amounted to $1.9 billion in 2024. This demonstrates the increasing penetration and economic significance of these innovative drug categories within the overall pharmaceutical landscape.

Digital Transformation in Healthcare Delivery
Another prominent trend reshaping the market is the accelerating digital transformation in healthcare delivery. This involves the widespread integration of digital technologies to enhance efficiency, accessibility, and the overall patient experience. Initiatives range from advanced electronic health record systems to the proliferation of telemedicine and mobile health applications, fundamentally altering how healthcare services are provided and accessed. The adoption of digital platforms allows for improved data management, streamlined patient journeys, and remote consultations, which are particularly beneficial for a diverse geographical landscape. According to the International Trade Administration, January 2026, Turkey's electronic health record system, e-Nabız, now covers more than 80% of the population. This widespread adoption underscores the deep integration of digital tools into the nation's healthcare infrastructure.

Segmental Insights

Policy Support, Demographics, and Domestic Capacity Drive Generics Growth
The generic drugs segment is the fastest-growing area within the Turkey Pharmaceuticals Market, primarily driven by increasing demand for affordable medications. This rapid expansion is underpinned by the nation's universal health coverage system and robust government policies from the Ministry of Health and the Turkish Medicines and Medical Devices Agency (TİTCK) that actively encourage generic drug utilization to manage healthcare expenditures. Furthermore, the rising prevalence of chronic diseases among an aging population necessitates cost-effective, long-term treatment options, which generics readily provide. Turkey's strong domestic manufacturing capacity also contributes significantly to the accessibility and growth of this segment.

Regional Insights

Market leadership driven by demographics and infrastructure
The Marmara region significantly leads the Turkey Pharmaceuticals Market, primarily driven by its unparalleled demographic and infrastructural advantages. This dominance stems from the region's highest population density, with Istanbul alone accounting for a substantial portion of the nation's residents, consequently generating immense demand for pharmaceutical products across all therapeutic areas. Furthermore, Marmara boasts Turkey's most advanced and concentrated healthcare infrastructure, featuring numerous public and private hospitals, specialized clinics, and extensive medical facilities. This robust healthcare ecosystem directly facilitates heightened pharmaceutical consumption, especially for complex and high-value treatments, solidifying its position as the preeminent market.

Recent Developments

• In August 2025, Santhera Pharmaceuticals finalized an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN), a leading Turkish specialty pharmaceuticals company. This collaboration focused on the distribution and promotion of AGAMREE® (vamorolone) in Türkiye. The medication is intended for the treatment of Duchenne muscular dystrophy in patients aged four years and older. The agreement stipulated that supply and sales by GEN were anticipated to commence in the first half of 2026, initially on a named patient basis, followed by broader commercial sales in the Turkish pharmaceuticals market.
• In May 2025, three innovative drug candidates developed in Türkiye were prepared to commence human trials. These candidates, which had been under development for four years at a research and development center in Istanbul, aimed to provide potential treatments for Alzheimer's disease, prostate cancer, and muscular atrophy. The Alzheimer's drug was designed to target neuronal hyperactivity, addressing both symptoms and underlying causes, while the prostate cancer treatment sought to prevent resistance to existing therapies. The muscular atrophy drug focused on preventing muscle loss and stimulating new muscle formation, representing a significant advancement in Turkey's pharmaceutical research capabilities.
• In January 2025, Bio-Thera, a biotechnology company, established an exclusive license and commercialization agreement with World Medicine, a Turkish pharmaceutical company. This collaboration focused on Bio-Thera's ustekinumab biosimilar, BAT2206, intended for the Turkish market. Under the terms, Bio-Thera was responsible for manufacturing the biosimilar in China, while World Medicine assumed responsibility for securing regulatory approval, managing importation, and overseeing the commercialization efforts for the product within Turkey. This partnership aimed to expand access to biosimilar treatments for patients in the country.
• In January 2024, Turkish Cargo, a prominent logistics provider, announced the introduction of three new pharmaceutical products named TK Pharma Standard, TK Pharma Extra, and TK Pharma Advanced. These offerings were designed to provide flexible and reliable solutions for the transportation of pharmaceutical and medical consignments within the Turkey Pharmaceuticals Market and globally. The products facilitated the shipment of temperature-sensitive cargo in adherence to industry standards, with options for active temperature control and continuous monitoring, thereby enhancing the integrity and safety of pharmaceutical supply chains in Turkey.

Key Market Players

• Abdi İbrahim İlaç Sanayi ve Ticaret A.Ş.
• Deva Holding A.Ş.
• Eczacıbaşı Pharmaceuticals Manufacturing S.A.
• Santa Farma İlaç Sanayii A.Ş.
• Bilim İlaç Sanayi ve Ticaret A.Ş.
• Bayer Türk Kimya Sanayi Ltd. Şti.
• Pfizer PFE İlaçları Ltd. Şti.
• Novartis Sağlık Gıda ve Tarım Ürünleri San. ve Tic. A.Ş.
• Sanofi Sağlık Ürünleri Ltd. Şti.
• Boehringer Ingelheim İlaç Ticaret A.Ş.

By Drug Type	By Product Type	By Application	By Distribution Channel	By Region
Branded Drugs Generic Drugs	Prescription Drugs Over-The-Counter Drugs	Oncology Metabolic Disorder Cardiovascular Anti-infective Musculoskeletal Others	Hospital Pharmacy Retail Pharmacy E-Pharmacy	Marmara Central Anatolia Aegean Mediterranean Black Sea South-Eastern Anatolia Eastern Anatolia

Report Scope:

In this report, the Turkey Pharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Turkey Pharmaceuticals Market, By Drug Type:

• Branded Drugs
• Generic Drugs

• Turkey Pharmaceuticals Market, By Product Type:

• Prescription Drugs
• Over-The-Counter Drugs

• Turkey Pharmaceuticals Market, By Application:

• Oncology
• Metabolic Disorder
• Cardiovascular
• Anti-infective
• Musculoskeletal
• Others

• Turkey Pharmaceuticals Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• E-Pharmacy

• Turkey Pharmaceuticals Market, By Region:

• Marmara
• Central Anatolia
• Aegean
• Mediterranean
• Black Sea
• South-Eastern Anatolia
• Eastern Anatolia